Atezolizumab & Chemotherapy Safe in Pleural Mesothelioma –

Doctors may recommend chemotherapy before surgery for pleural mesothelioma. However, some patients may experience tumor progression during chemotherapy treatment. As a result, they could become ineligible for surgery. Patients who experience this may find it disheartening. Research shows treatment plans that include surgery can improve survival.
Researchers recently presented data that may help mesothelioma patients feel more confidence in pre-surgery treatment. In the study, pleural mesothelioma patients received chemotherapy and immunotherapy prior to surgery. This treatment regimen kept tumors from progressing for about one and a half years.
The immunotherapy drug in this study is called atezolizumab. It is also known by its brand name, Tecentriq®. Atezolizumab has not been extensively studied in pleural mesothelioma. As such, researchers needed to evaluate atezolizumab’s safety before looking at its efficacy.
To do so, researchers only tested the new treatment approach. The new approach has not yet been compared to traditional pre-surgical chemotherapy.
Atezolizumab is an immunotherapy drug. It belongs to a class of drugs called checkpoint inhibitors. Checkpoint inhibitors help prevent cancer cells from evading the immune system.
Atezolizumab interferes with the PD-L1 checkpoint. This allows the patient’s immune cells to target and kill cancer cells. Other immunotherapy drugs such as nivolumab (Opdivo®) also target this checkpoint.
The study plan called for all enrolled patients to undergo the same general treatment regimen:
Doctors monitored patients closely for reactions related to atezolizumab. If no patients experienced certain severe side effects, the treatment approach would be considered safe.
At last follow-up, study patients had not experienced any severe side effects from atezolizumab. As a result, researchers determined this new treatment approach meets safety criteria.
Since the new regimen meets safety criteria, additional studies may compare the following:
An additional study could determine if adding atezolizumab improves survival versus chemotherapy alone. The current study is not designed to make that determination. However, researchers are monitoring survival.
Note: All enrolled patients were deemed eligible for surgery at the time of enrollment. The study did not test this new treatment regimen in patients with inoperable pleural mesothelioma.
Researchers had been following study patients for about 20 months as of September 2021. At that time, the study had not yet reached a median survival. Thus, the median survival will be better than 20 months.
An earlier study found a median survival of 18 months for traditional cancer-directed pleural mesothelioma treatment. As such, this new approach may represent a substantial improvement once results are final.
Researchers also reported median progression-free survival (PFS). Median PFS is the point at which half of patients have experienced mesothelioma growth and half have not. Patients achieved a median PFS of 18.6 months with the new treatment regimen.
Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center is one of the lead researchers on the study. He recently spoke with The ASCO Post about these results. Dr. Sepesi called the performance of pre-surgical atezolizumab and chemotherapy “rather encouraging.”
However, Dr. Sepesi refused to even speculate about the regimen’s efficacy because the study is not yet complete. His position may remain unchanged even when the study wraps because it was not designed to evaluate efficacy.
Despite Dr. Sepesi’s tempered enthusiasm, mesothelioma patients may find this study “rather encouraging.” Doctors found atezolizumab safe as an addition to presurgical chemotherapy. In addition, the new treatment approach kept mesothelioma from progressing for about one and a half years.
Investigators will have to perform additional research to understand the efficacy of this new combination. In the meantime, patients may be able to access atezolizumab by participating in a clinical trial.
Any mesothelioma patient interested in a clinical trial should discuss treatment options with a doctor. A mesothelioma specialist can help the patient understand the best treatment approach for their situation.
Rusch VW, Giroux D, et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. Journal of Thoracic Oncology. November 2012;7(11):1631-1639. doi: 10.1097/JTO.0b013e31826915f1
Tsao A. A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma. Presented September 2021. World Conference on Lung Cancer.
U.S. Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION: TECENTRIQ® (atezolizumab) injection, for intravenous use.
Voigt SL, Raman V, et al. The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis. Journal of the National Cancer Institute. November 2020;112(11):1118-1127. doi: 10.1093/jnci/djaa002
Weder W, Kestenholz P, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Journal of Clinical Oncology. September 2004;22(17):3451-7. doi: 10.1200/JCO.2004.10.071
By Katy Moncivais, Ph.D.
By Katy Moncivais, Ph.D.
By Katy Moncivais, Ph.D. is dedicated to providing the latest medical information on mesothelioma, spreading awareness about the dangers of asbestos exposure and providing victims with free resources.
En Español:
¿Qué es el cáncer de mesotelioma?

The editorial team works hard to offer current, factual, expert reviewed information about mesothelioma cancer and the risks of asbestos exposure.
Editorial Guidelines | Disclaimer | Privacy Policy
35 Thorpe Avenue, Suite 101
Wallingford, CT 06492
This site complies with the HONcode standard for trustworthy health information:
verify here.
Copyright © 2021 by All Rights Reserved. The information contained on this site is proprietary and protected. Any unauthorized or illegal use, copying or dissemination will be prosecuted to the fullest extent of the law.
Notice: This website and its content are sponsored by Early, Lucarelli, Sweeney, & Meisenkothen, LLC, a law firm specializing in asbestos injury litigation.
Attorney Advertising. Prior results do not predict a similar outcome. Please read our disclaimer for more information.
Page last modified on November 18, 2021.


Related posts

Leave a Reply

Your email address will not be published.